Lesson 1: What is Biotechnology Entrepreneurship, and Why It’s Different from Every Other Industry

This article was originally published as part of the Biotech Entrepreneurship: What “I Wish Someone Told Me” series on my LinkedIn page. It is republished here on my BioSource Consulting website for long‑form reference and educational use.

Many people unknowingly hold a simplistic mental model of entrepreneurship, often reduced to a linear sequence:

Develop an idea
Raise capital
Commercialize a product.

In the tech industry, there is a familiar rhythm: build → ship → learn → iterate. Development time is rapid, and customer feedback arrives fast. Product changes are deployed quickly to respond to the market. There are many challenges in building a technology company; however, it is important to recognize the fundamental differences between biotech entrepreneurship and entrepreneurship in other industries.

Biotechnology entrepreneurship is not simply “entrepreneurship with a lab attached.” Unlike entrepreneurship in other industries, in biotechnology:

You cannot “fail fast” when experiments take months and cost hundreds of thousands of dollars.
You cannot “pivot” away from a core biological hypothesis without destroying prior investment and market opportunity.
You cannot iterate on a clinical program the way you can iterate on a user interface.

Biotechnology involves a unique combination of disciplines, influenced by biology, intense capital requirements, stringent regulation, long development timelines, and the obligation that comes with developing products that impact human health. These factors change how entrepreneurs must think, decide, and act.

Although understanding this doesn’t make it easier, it does make it more navigable. Below, I’ve highlighted three of the many elements that make building biotechnology companies vastly different from entrepreneurial companies in other industries:

1) When You Combine Biology and Business, You Create a Business of Uncertainty

One of the most important—and least appreciated—realities of biotechnology entrepreneurship is that when you combine biology and business, you do not simply create a technology company. You create a business of uncertainty.

Biotechnology companies are built on biological systems that are complex and variable. Even when experiments are well designed, outcomes are not always predictable. Promising results may not replicate. Unexpected findings may appear late. These experiences are not signs of failure; they are normal when working with biology.

For leadership teams, this means uncertainty is constant. Biological uncertainty cannot be eliminated; it can be reduced, managed, and better understood over time, yet it never fully disappears. Therefore, the role of the biotechnology leader is to learn to operate effectively within this level of uncertainty. Essentially the entrepreneur becomes the Chief Uncertainty Officer. They are responsible for identifying the biological and business risks facing the organization, designing strategies to reduce them, communicating tradeoffs, and maintaining team unity as knowledge evolves.

This may include:

• Making decisions with incomplete information, while remaining open to change.

• Choosing experiments that reduce the most critical risks.

• Communicating uncertainty to boards, investors, and teams.

• Avoiding the temptation to oversimplify complex scientific realities.

Biotechnology companies are being built and operate in the midst of many unanswered biological questions. This is one critical factor in why biotechnology entrepreneurship fundamentally differs from entrepreneurship in other industries.

2) The Entrepreneur Owns Both Scientific and Business Risk

In a traditional business enterprise, the entrepreneur is primarily responsible for the business risk, that includes the market risk, financial risk, and execution risk. In a biotechnology company, scientific uncertainty is not separate from the business; it is embedded within it.

The entrepreneur is responsible for both the business risk and the scientific risk.

This dual responsibility is one reason why many biotech companies are founded by scientists and physicians. This dual responsibility often surprises first‑time biotechnology entrepreneurs. Decisions about experimental design, data interpretation, and biological feasibility directly affect capital allocation, partnerships, hiring, and timelines.

In biotechnology, leaders must make decisions before all the answers are known, because biological outcomes shape business strategy.

Scientific results may:

Delay or accelerate development timelines
Change the addressable market
Alter regulatory pathways
Force reconsideration of partnerships or business models

In biotechnology, business considerations often shape scientific direction

For example:

Market needs define which scientific questions are worth pursuing.
Regulatory requirements influence experimental design and data collection.
Manufacturing feasibility shapes the early research conducted.
Capital constraints force prioritization among competing scientific paths.

This dynamic—the business driving the science and the science driving the business—is the core distinction between basic research and translational research, a topic I will explore in future articles.

3) Biotechnology Entrepreneurship Requires Long Timeframes and Lots of Money

Biotechnology companies are built over long periods of time, spanning many, many years.

Diagnostic companies may require 3 to 7 years or more
Medical device companies often require 4 to 10 years or more
Therapeutic and biologic companies can span 10 to 15 years or longer

Development timelines are extended because biological data must be generated, repeated, interpreted, and validated before it can reliably support decision-making. In addition, biotechnology is one of the most highly regulated industries in the world. Regulatory expectations affect what data must be generated, how it must be generated, and how results can be communicated.

Timelines affect financing strategy, hiring plans, and partnership decisions. These realities influence nearly every strategic decision a leadership team makes.

Building biotechnology companies is capital intensive, and requires multiple, successive, timely, and large investments of capital.

Diagnostic companies may require $20 to $100 million or more
Medical device companies may require from $25 to $120 million or more
Therapeutic and biologic companies may require hundreds of millions to over $2.6 billion before reaching market

Many early failures in biotechnology stem not from bad science, but often from a misunderstanding of the time and capital required to build, sustain, and grow a biotechnology company.

Takeaway Thoughts

For scientists, physicians, and executives who are biotechnology entrepreneurs, a few observations are worth keeping in mind:

Biotech entrepreneurship is fundamentally different from other industries, defined by biological uncertainty, regulation, long timelines, and capital intensity. Set your expectations realistically. Design your company, financing strategy, runway and risk reducing milestones around these.

Biotech leaders operate in persistent uncertainty, making high‑stakes decisions before all scientific answers are known. It is impossible to have all the information you need to make every decision. However, create a decision framework for yourself based upon outcome risk coupled to your requirement for different levels and types of information you want before making different decisions.

Science and business are inseparable for a biotech entrepreneur, with time and capital as core strategic variables and constraints. Treat capital and time like experimental inputs. Every scientific decision should have a clear business rationale, and every business decision should respect the biological limits and reality.

For those who wish to explore this topic further, Elsevier has authorized a free download of my Chapter 1, “What Is Biotechnology Entrepreneurship?” I wish you the best of success in your entrepreneurial journey.